Titrating Norepinephrine (Levophed)
Start norepinephrine at 8-12 mcg/min (0.5-1 mL/min of standard 4 mcg/mL dilution), titrate every 2-5 minutes to achieve a target MAP of 65 mmHg, with average maintenance doses of 2-4 mcg/min.
Initial Setup and Dilution
The FDA-approved preparation requires diluting 4 mg (4 mL vial) in 1,000 mL of 5% dextrose solution, yielding a concentration of 4 mcg/mL 1. Critically, use dextrose-containing solutions only—saline alone is not recommended as it fails to protect against oxidation-related potency loss 1. Administer through a large central vein via a securely fixed plastic catheter to minimize extravasation risk 1.
Target Blood Pressure
The initial MAP target should be 65-70 mmHg for septic shock patients 2, 3, 2, 4, 2. This represents the strongest guideline recommendation (strong recommendation, moderate quality evidence) from the 2016 Surviving Sepsis Campaign 2, 3. The most recent 2025 ESICM guidelines reaffirm this 65-70 mmHg target as an ungraded good practice statement 5.
When to Target Higher MAP
Consider targeting higher MAP (75-85 mmHg) in two specific scenarios:
- Chronic hypertension with clinical improvement at higher pressures: Patients with pre-existing hypertension may require MAP 40 mmHg below their baseline systolic pressure 1
- Elevated central venous pressure (CVP): Higher MAP may be needed when CVP is elevated to maintain adequate perfusion pressure gradient 5
Titration Protocol
Starting Dose
Begin with 8-12 mcg/min (2-3 mL/min of standard dilution) 1. This translates to approximately 0.1-0.15 mcg/kg/min for a 70-80 kg patient.
Titration Frequency
Adjust the infusion rate every 2-5 minutes based on blood pressure response 1. The FDA label emphasizes using an IV drip chamber or metering device to permit accurate flow rate estimation 1. Recent research demonstrates that more frequent adjustments (automated systems making changes every 1-2 minutes) significantly reduce hypotensive episodes compared to manual titration 6, 7.
Maintenance Dosing
Average maintenance doses range from 2-4 mcg/min (0.5-1 mL/min) 1. However, individual variation is substantial—some patients require much higher doses.
High-Dose Considerations
Doses as high as 68 mg base daily (approximately 47 mcg/min continuous) may be necessary 1. When patients remain hypotensive despite escalating doses, always suspect and correct occult blood volume depletion 1. Central venous pressure monitoring is particularly helpful in this situation 1.
Critical Pitfalls
Volume Status First
Blood volume depletion must be corrected as fully as possible before initiating vasopressors 1. The Surviving Sepsis guidelines recommend an initial fluid bolus of at least 30 mL/kg crystalloids before or concurrent with vasopressor initiation 4, 2, 4.
Avoid Abrupt Withdrawal
Reduce norepinephrine gradually when discontinuing—abrupt withdrawal can precipitate hemodynamic collapse 1. Some patients with acute myocardial infarction have required treatment for up to 6 days 1.
Monitoring Requirements
Place an arterial catheter as soon as practical in all patients requiring vasopressors 4, 2. This allows for continuous, accurate blood pressure monitoring essential for safe titration.
Evidence on Higher MAP Targets
Research shows conflicting results on targeting MAP above 65 mmHg. One study found that increasing MAP from 65 to 85 mmHg with norepinephrine did not improve microcirculatory flow and showed a trend toward decreased capillary perfused density 8. However, patients with baseline poor microcirculation showed inverse correlation—those with better baseline perfusion worsened with higher MAP targets 8. In cardiogenic shock, short-term up-titration to MAP 85 mmHg was well-tolerated without worsening cardiac function 9.
Practical Dose-Response Relationship
Recent volunteer data suggests a linear relationship: under general anesthesia, the required norepinephrine dose can be estimated as (target MAP - 54)/222 μg/kg/min 10. While this provides a starting framework, clinical titration based on individual response remains essential as the relationship varies significantly between patients and clinical contexts.
Adding Second-Line Agents
When norepinephrine alone is insufficient, add vasopressin (0.03 units/min) or epinephrine rather than escalating norepinephrine to extremely high doses 2, 3, 2. Vasopressin can either raise MAP further or allow reduction of norepinephrine dose 2, 3.